Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jul;39(7):1599–1602. doi: 10.1128/aac.39.7.1599

Activity of penciclovir against Epstein-Barr virus.

T H Bacon 1, M R Boyd 1
PMCID: PMC162789  PMID: 7492112

Abstract

Penciclovir inhibited the productive replication cycle of Epstein-Barr virus (EBV) in assays measuring infectious virus production, viral antigen expression, and viral DNA synthesis. In the test measuring inhibition of EBV DNA synthesis, 50% effective concentrations of penciclovir and acyclovir were 2.3 +/- 0.8 and 2.2 +/- 0.6 micrograms/ml, respectively. The 50% cell growth inhibitory concentration of penciclovir was > 100 micrograms/ml for both P3HR-1 and Raji cells. Penciclovir is a selective inhibitor of EBV in cell culture.

Full Text

The Full Text of this article is available as a PDF (178.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson J., Britton S., Ernberg I., Andersson U., Henle W., Sköldenberg B., Tisell A. Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study. J Infect Dis. 1986 Feb;153(2):283–290. doi: 10.1093/infdis/153.2.283. [DOI] [PubMed] [Google Scholar]
  2. Arrand J. R., Rymo L., Walsh J. E., Björck E., Lindahl T., Griffin B. E. Molecular cloning of the complete Epstein-Barr virus genome as a set of overlapping restriction endonuclease fragments. Nucleic Acids Res. 1981 Jul 10;9(13):2999–3014. doi: 10.1093/nar/9.13.2999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boyd M. R., Bacon T. H., Sutton D. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals. Antimicrob Agents Chemother. 1988 Mar;32(3):358–363. doi: 10.1128/aac.32.3.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boyd M. R., Bacon T. H., Sutton D., Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother. 1987 Aug;31(8):1238–1242. doi: 10.1128/aac.31.8.1238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chiou J. F., Cheng Y. C. Interaction of Epstein-Barr virus DNA polymerase and 5'-triphosphates of several antiviral nucleoside analogs. Antimicrob Agents Chemother. 1985 Mar;27(3):416–418. doi: 10.1128/aac.27.3.416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Colby B. M., Furman P. A., Shaw J. E., Elion G. B., Pagano J. S. Phosphorylation of acyclovir [9-(2-hydroxyethoxymethyl)guanine] in Epstein-Barr virus-infected lymphoblastoid cell lines. J Virol. 1981 May;38(2):606–611. doi: 10.1128/jvi.38.2.606-611.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Colby B. M., Shaw J. E., Elion G. B., Pagano J. S. Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J Virol. 1980 May;34(2):560–568. doi: 10.1128/jvi.34.2.560-568.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Datta A. K., Colby B. M., Shaw J. E., Pagano J. S. Acyclovir inhibition of Epstein-Barr virus replication. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5163–5166. doi: 10.1073/pnas.77.9.5163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Earnshaw D. L., Bacon T. H., Darlison S. J., Edmonds K., Perkins R. M., Vere Hodge R. A. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother. 1992 Dec;36(12):2747–2757. doi: 10.1128/aac.36.12.2747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gadler H., Larsson A., Sølver E. Nucleic acid hybridization, a method to determine effects of antiviral compounds on herpes simplex virus type 1 DNA synthesis. Antiviral Res. 1984 Apr;4(1-2):63–70. doi: 10.1016/0166-3542(84)90026-3. [DOI] [PubMed] [Google Scholar]
  11. Henle G., Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol. 1966 Mar;91(3):1248–1256. doi: 10.1128/jb.91.3.1248-1256.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hinuma Y., Konn M., Yamaguchi J., Wudarski D. J., Blakeslee J. R., Jr, Grace J. T., Jr Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. J Virol. 1967 Oct;1(5):1045–1051. doi: 10.1128/jvi.1.5.1045-1051.1967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hodge R. A., Perkins R. M. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother. 1989 Feb;33(2):223–229. doi: 10.1128/aac.33.2.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Klein G., Giovanella B., Westman A., Stehlin J. S., Mumford D. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology. 1975;5(6):319–334. doi: 10.1159/000149930. [DOI] [PubMed] [Google Scholar]
  15. Lin J. C., Smith M. C., Pagano J. S. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J Virol. 1984 Apr;50(1):50–55. doi: 10.1128/jvi.50.1.50-55.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Littler E., Arrand J. R. Characterization of the Epstein-Barr virus-encoded thymidine kinase expressed in heterologous eucaryotic and procaryotic systems. J Virol. 1988 Oct;62(10):3892–3895. doi: 10.1128/jvi.62.10.3892-3895.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Littler E., Zeuthen J., McBride A. A., Trøst Sørensen E., Powell K. L., Walsh-Arrand J. E., Arrand J. R. Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO J. 1986 Aug;5(8):1959–1966. doi: 10.1002/j.1460-2075.1986.tb04450.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Miller G., Robinson J., Heston L., Lipman M. Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference. Proc Natl Acad Sci U S A. 1974 Oct;71(10):4006–4010. doi: 10.1073/pnas.71.10.4006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. PULVERTAFT J. V. CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA). Lancet. 1964 Feb 1;1(7327):238–240. doi: 10.1016/s0140-6736(64)92345-1. [DOI] [PubMed] [Google Scholar]
  20. Pagano J. S., Sixbey J. W., Lin J. C. Acyclovir and Epstein-Barr virus infection. J Antimicrob Chemother. 1983 Sep;12 (Suppl B):113–121. doi: 10.1093/jac/12.suppl_b.113. [DOI] [PubMed] [Google Scholar]
  21. Rabalais G. P., Levin M. J., Berkowitz F. E. Rapid herpes simplex virus susceptibility testing using an enzyme-linked immunosorbent assay performed in situ on fixed virus-infected monolayers. Antimicrob Agents Chemother. 1987 Jun;31(6):946–948. doi: 10.1128/aac.31.6.946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Resnick L., Herbst J. S., Ablashi D. V., Atherton S., Frank B., Rosen L., Horwitz S. N. Regression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA. 1988 Jan 15;259(3):384–388. [PubMed] [Google Scholar]
  23. Tung P. P., Summers W. C. Substrate specificity of Epstein-Barr virus thymidine kinase. Antimicrob Agents Chemother. 1994 Sep;38(9):2175–2179. doi: 10.1128/aac.38.9.2175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. de Miranda P., Blum M. R. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983 Sep;12 (Suppl B):29–37. doi: 10.1093/jac/12.suppl_b.29. [DOI] [PubMed] [Google Scholar]
  25. van der Horst C., Joncas J., Ahronheim G., Gustafson N., Stein G., Gurwith M., Fleisher G., Sullivan J., Sixbey J., Roland S. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. J Infect Dis. 1991 Oct;164(4):788–792. doi: 10.1093/infdis/164.4.788. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES